[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100493758":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":46,"collaborators":20,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":20,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":20,"enrollmentInfo":57,"targetDuration":20,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Amydis Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"AMDX-2011P 100 mg","EXPERIMENTAL","AMDX2011P 100mg (4ml) single bolus injection intravenous for diagnostic review",[13],"Drug: AMDX-2011P",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","AMDX-2011P","AMDX-2011P single bolus injection intravenous for diagnostic review",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Matthew Lehman","CONTACT","8599050402","info@amydis.com",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Associated Retina Consultants","RECRUITING","Phoenix","Arizona","85020","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-112.07404,33.44838,{"lat":40,"lon":39},[43],{"name":44,"role":24,"phone":20,"phoneExt":20,"email":45},"Mallory Mintert","mallory.mintert@doctrials.com",{"type":47,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100493758","phase-2-a-study-of-amdx-2011p-in-participants-with-caa-100493758",false,"NCT05709314","A Study of AMDX-2011P in Participants With CAA","A Phase 2, Open-Label Study of AMDX-2011P as a Retinal Tracer in Participants With Cerebral Amyloid Angiopathy (CAA)","Inclusion Criteria:\n\n1. Diagnosis of hereditary CAA or probable and definite symptomatic or asymptomatic sporadic CAA diagnosed through genetic testing or according to the modified Boston neuroradiological criteria, who had undergone at least one brain magnetic resonance imaging (MRI)prior to entry into study.\n2. Abnormality consistent with CAA on historical MRI.\n3. In general good health\n\nExclusion Criteria:\n\n1. Presence of any underlying physical or psychological medical condition that, in the opinion of the investigator, would make it unlikely that the participant will complete the study per protocol.\n2. Clinically significant laboratory abnormalities assessed by the investigator.\n3. Active malignancy and\u002For history of malignancy in the past 5 years, with the exception of completely excised non-melanoma skin cancer or low-grade cervical intraepithelial neoplasia.\n4. Prolonged QTcF (\\>450 ms for males and \\>470 ms for females),cardiac arrhythmia, or any clinically significant abnormality in the resting ECG, as judged by the investigator.","ALL","18 Years",{"count":58,"type":59},25,"ESTIMATED","INTERVENTIONAL",[62],"PHASE2","The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).",[65],"Cerebral Amyloid Angiopathy",[67],"CAA","2026-02-11",{"date":70,"type":71},"2026-02-13","ACTUAL",{"date":73,"type":71},"2024-07-09",{"date":75,"type":59},"2026-12",{"name":5,"class":6},1]